NKE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nike Inc (NKE) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock faces significant headwinds, including weak financial performance, a slow turnaround, and cautious analyst sentiment. While insider purchases and upcoming events like the NBA Playoffs and World Cup could provide some positive momentum, the lack of short-term catalysts and bearish technical indicators suggest waiting for clearer signs of recovery before investing.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 52.798, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting the stock is in a downtrend. Key resistance levels are at R1: 45.838 and R2: 46.876, while support levels are at S1: 42.476 and S2: 41.438.
Insider purchases by executives Tim Cook and Elliott Hill signal confidence in the company's future.
Upcoming global events like the NBA Playoffs, World Cup, and Olympics could drive brand visibility and sales.
The company's efforts to clean up inventory and rebalance its product portfolio are steps in the right direction.
Weak Q4 sales forecast and significant revenue decline in China.
Analysts have downgraded the stock, citing slow turnaround and limited innovation.
Financial performance shows declining net income (-34.51% YoY) and EPS (-35.19% YoY).
The stock remains expensive at 33x FY27 EPS, with limited upside potential in the near term.
In Q3 2026, Nike's revenue increased marginally by 0.09% YoY to $11.28 billion. However, net income dropped significantly by 34.51% YoY to $520 million, and EPS fell by 35.19% YoY to $0.35. Gross margin also declined by 3.21% YoY to 40.16%. These figures indicate weak profitability and growth trends.
Analysts have downgraded the stock significantly. HSBC downgraded Nike to Hold with a price target of $48, citing a lack of short-term catalysts and weak performance in key markets. Piper Sandler downgraded it to Neutral with a price target of $50, citing industry saturation and insufficient innovation. Other firms have also lowered price targets, reflecting cautious sentiment and a slow recovery process.
